Considering the diversity of current treatments for esophageal cancer and the selectivity of current targeted therapy drugs, the NCCN guidelines also point out that targeted therapy drugs for esophageal cancer include anti-EGFR monoclonal antibodies such as nimotuzumab, or, for EGFR gene mutations, such as gefitinib and erlotinib. This evidence concerns the gene EGFR and esophageal cancer.